The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.
To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:
TAG, with support from Wellcome, is conducting a scoping exercise of community partners and interventions to support new TB vaccine readiness.
TAG is pleased to share the latest edition of our Tuberculosis Vaccines Pipeline Report, written by TB project co-director Mike Frick. The report provides the latest information on 17 vaccine candidates under clinical development and summarizes ongoing, planned, and recently completed clinical trials in two comprehensive tables.
Treatment Action Group (TAG) opposes in the strongest possible terms the termination of National Institutes of Health (NIH) research awards and contracts to South Africa, feared following reporting by Science.
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP). It’s addressed to Congressional leaders and urges Congress to adamantly reject all proposals to enact cuts to Medicaid, a vital source of HIV prevention, treatment, and care.
TAG submitted this this input for the Office of the High Commissioner on Human Rights (OHCHR), in response to its request for "Inputs for the comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products."
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.